The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.

Abstract

Mutations in isocitrate dehydrogenases (IDHs) have a gain-of-function effect leading to R(-)-2-hydroxyglutarate (R-2HG) accumulation. By using biochemical, structural and cellular assays, we show that either or both R- and S-2HG inhibit 2-oxoglutarate (2OG)-dependent oxygenases with varying potencies. Half-maximal inhibitory concentration (IC(50)) values for the R-form of 2HG varied from approximately 25 μM for the histone N(ɛ)-lysine demethylase JMJD2A to more than 5 mM for the hypoxia-inducible factor (HIF) prolyl hydroxylase. The results indicate that candidate oncogenic pathways in IDH-associated malignancy should include those that are regulated by other 2OG oxygenases than HIF hydroxylases, in particular those involving the regulation of histone methylation.

DOI: 10.1038/embor.2011.43

4 Figures and Tables

05002011201220132014201520162017
Citations per Year

3,300 Citations

Semantic Scholar estimates that this publication has 3,300 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Chowdhury2011TheO2, title={The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.}, author={Rasheduzzaman Chowdhury and Kar Kheng Yeoh and Ya-Min Tian and Lars Hillringhaus and Eleanor A Bagg and Nathan R Rose and Ivanhoe K H Leung and Xuan S Li and Esther C Y Woon and Ming Yang and Michael A McDonough and Oliver N King and Ian J Clifton and Robert J Klose and Timothy D W Claridge and Peter J Ratcliffe and Christopher J Schofield and Akane Kawamura}, journal={EMBO reports}, year={2011}, volume={12 5}, pages={463-9} }